|
| Status |
Public on Jul 12, 2010 |
| Title |
F40-7-V |
| Sample type |
RNA |
| |
|
| Source name |
MCF-7, fulvestrant resistant, vehicle treated
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: MCF-7
cell type: cancer cell culture
resistance: fulvestrant
subline: 40-7
treatment: vehicle
|
| Treatment protocol |
Vehicle (0.1% ethanol = 1000X working stock solution) was added directly to cell culture (10 microliter for a 10-cm dish containing 10 ml medium). Cells were incubated for 48 hours, and their total RNA was isolated for transcriptomal analysis.
|
| Growth protocol |
MCF-7/BUS cell culture was maintained in high-glucose, phenol red-free DMEM (PF-DMEM) and supplemented with 5% fetal calf serum.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
QIAGEN RNeasy protocol and reagents for extraction of total RNA
|
| Label |
biotin
|
| Label protocol |
Affymetrix One-Cycle Target Labeling and Control Reagents (Part#900493) + Enzo BioArray High Yield RNA Transcript Labelling Kit (Part#42655)
|
| |
|
| Hybridization protocol |
Microarray = Affymetrix GeneChip Human Genome U133 Plus 2.0. Affymetrix Hybridization Oven= 645. Affymetrix Fluidics Station= 450. Fluidics Protocol= EukGE-WS2
|
| Scan protocol |
Affymetrix GeneChip Scanner= 3000-7G. Controller= GCOS
|
| Description |
vehicle treated, fulvestrant resistant MCF-7 sub-line 40-7
|
| Data processing |
MAS5 algorithm as implemented by call.exprs function of Bioconductor simpleaffy package version 2.14.05, 2% trimmed mean set to 100
|
| |
|
| Submission date |
Jul 12, 2010 |
| Last update date |
Jul 12, 2010 |
| Contact name |
Ben S. Wittner |
| E-mail(s) |
[email protected]
|
| Organization name |
Massachusetts General Hospital
|
| Department |
Center for Cancer Research
|
| Lab |
Lawrence
|
| Street address |
149 13th Street
|
| City |
Boston |
| State/province |
MA |
| ZIP/Postal code |
02129 |
| Country |
USA |
| |
|
| Platform ID |
GPL570 |
| Series (1) |
| GSE14986 |
Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common clonal drug-resistant progenitor |
|
